Global Neurodegenerative Disease
Market Report
2024
Neurodegenerative Disease Market Report 2024 (Global Edition)
Delivery Includes:- Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Neurodegenerative Disease Market Report 2024.
Global Neurodegenerative Disease Market Report 2024 Market Size Split by Disease indication (Parkinson's' Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington's Disease), by Drug (N-Methyl-D-...
According to cognitive market research, the global neurodegenerative diseases market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.
- The gradual degradation of the structure and function of the central or peripheral nervous systems is a hallmark of a wide spectrum of illnesses known as neurodegenerative diseases.
- Several significant patents related to neurodegenerative diseases are set to expire in the future years, posing issues for the industry.
- In the global market for neurodegenerative diseases, telemedicine and digital health technologies offer substantial prospects for transforming patient care and illness management.
- By focusing on underlying inflammatory pathways, the medications have the potential to alter the course of the disease, giving patients hope for better outcomes and symptom control
- Research groups and pharmaceutical corporations are working harder to create disease-modifying treatments that go after underlying pathological processes like tau and amyloid-beta protein aggregation
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Market Size | 121212 |
| Country Market Size | 121212 |
| North Americ Market Size | 121212 |
| Europe Market Size | 121212 |
| Asia Pacific Market Size | 121212 |
| South America Market Size | 121212 |
| Middle East and Africa Market Size | 121212 |
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
| |
| Market Split by Disease indication |
|
| Market Split by Drug |
|
| Market Split by Distribution Channel |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Neurodegenerative Disease industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Neurodegenerative Disease Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Neurodegenerative Disease Market Report Description
Introduction of the Neurodegenerative Disease Market
The gradual degradation of the structure and function of the central or peripheral nervous systems is a hallmark of a wide spectrum of illnesses known as neurodegenerative diseases. Globally, there has been an increase in neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, and Huntington's disease. Consequently, the key driver of market expansion is the increasing prevalence of this condition, which is further fueled by an ageing population.
A wide range of pharmaceutical methods targeted at symptom relief, disease progression slowing, and improved patient outcomes define the global market for neurodegenerative diseases. Medications that target neurotransmitter systems, such as dopamine agonists for Parkinson's disease or cholinesterase inhibitors for Alzheimer's disease, are part of traditional therapy. But thanks to recent developments, patients and carers now have new hope thanks to the development of disease-modifying medications, precision medicine interventions, immunomodulatory drugs, gene therapies, and stem cell-based treatments.
Market Dynamics of the Neurodegenerative Disease Market
Key Drivers of the Neurodegenerative Disease Market
- The rising prevalence of neurological disorders will significantly drive market growth
The average lifespan and population growth have led to an increase in the prevalence of neurological illnesses globally. By 2020, there will be more Americans living with Parkinson's disease than with multiple sclerosis, muscular dystrophy, and Lou Gehrig's disease combined, according to the Parkinson's Foundation, which projects that about one million individuals will have the condition in the US. According to the Alzheimer's Association, 5.8 million Americans are expected to have Alzheimer's disease in 2019. As the global population grows, these illnesses become more common in people of various racial and gender identities as well as in different geographic locations. The data indicates that the market has grown throughout the course of the investigation, possibly due to an increase in the prevalence of neurodegenerative illnesses.
• For instance, in 2021, 3.4 billion people experienced a nervous system condition, according to a major new analysis from the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) 2021, published in The Lancet Neurology journal.
(Source:https://www.healthdata.org/news-events/newsroom/news-releases/lancet-neurology-neurological-conditions-now-leading-cause-ill#:~:text=Globally%2C%20the%20number%20of%20people,exposure%20to%20environmental%2C%20metabolic%2C%20and )
- Increasing public awareness about neurodegenerative diseases will boost the market expansion
Various non-governmental organisations and the government have been working nonstop to raise public awareness. To increase awareness of Parkinson's disease, for example, the Parkinson's Disease community observes Parkinson's Disease (PD) month in April. April is recognised as Parkinson's Disease Awareness Month, a time when the already vibrant Parkinson's disease community ramps up events to raise awareness of the condition. To promote fresh research on dementia, Eisai Co. Ltd. and the UK Dementia Research Institute (UK DRI) launched a collaborative postdoctoral programme in May 2019. This unique industrial partnership for the UK DRI aims to provide cutting-edge research that may result in improvements in dementia prevention, diagnosis, and treatment in general. Furthermore, March is designated as Multiple Sclerosis Awareness Month in the US to raise awareness of the condition's current state of research as well as potential new treatments and diagnoses.
• For instance, in June 2022, the Food and Drug Administration launched an action plan for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS). This action plan is the five-year strategy implemented to improve and extend the lives of people living with rare neurodegenerative diseases across the country.
(Source:https://www.fda.gov/media/159372/download )
Restraint of the Neurodegenerative Disease Market
- Patent expiry of neurodegenerative disease treatment products
Several significant patents related to neurodegenerative diseases are set to expire in the future years, posing issues for the industry. This tendency will cause generic alternatives to enter the market, which will increase competition and drive down prices. Despite a rise in medication volume, it is anticipated that the availability of several generics under one brand name would drive costs even down and reduce the industry's total value. The previously authorised generic versions of these medications may be sold for less when they expire. The trend thus poses a significant challenge for pharmaceutical companies, impacting the revenue streams and potentially stalling innovation in the neurodegenerative disease treatment sector. As a result, the tendency presents a serious problem for pharmaceutical firms, affecting their income streams and perhaps impeding innovation in the field of treating neurodegenerative diseases.
• For instance, in 2020, Teva/Lundbeck's Azilect/Agilent (rasagiline) used to treat Parkinson's disease was found to be expired. Also, there is increasing generic competition in the market that includes the ropinirole (GlaxoSmithKline's Requip and GSK/SkyePharma's Requip XL/LP/RP/Modutab/Prolib).
(Source:https://www.tevapharm.com/news-and-media/latest-news/fda-approves-expanded-label-for-azilect-for-treatment-across-all-stages-of-parkinsons-disease/ )
How Did COVID-19 Impact The Neurodegenerative Diseases Market
Although there was a strong late-stage product pipeline, COVID-19 had a relatively modest growth due to its influence on the workflows of clinical trials, research, development, and pipeline products for neurodegenerative illnesses. This had a substantial effect on the market. The pandemic-related delays in product approvals had a big effect on how the industry developed. A modification in the administration of Disease-Modifying Therapies was reported by nearly 10% of participants, indicating postponements and delays in therapy. As a result of the COVID-19 pandemic's severe financial impact on several organisations, low-cost generics have become more popular. Moreover, the pandemic hurt the introduction of new products, which is the most important factor in the market's expansion.
• For instance, in January 2021, Biogen and Eisai Co. Ltd reported the United States Food and Drug Administration (FDA) extended the review period by three months for the Biologics License Application for aducanumab, an investigational treatment for Alzheimer's disease.
(Source:https://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-announce-fdas-3-month-extension-review-period )
Opportunities of the Neurodegenerative Disease Market
- Telemedicine and digital health are significant opportunities for the market
In the global market for neurodegenerative diseases, telemedicine and digital health technologies offer substantial prospects for transforming patient care and illness management. These technologies optimise the use of healthcare resources, improve patient outcomes, and increase access to healthcare services through the use of digital platforms, remote monitoring devices, and communication tools. Neurology professionals may evaluate and monitor patients with neurodegenerative illnesses remotely using telemedicine, offering prompt consultations, medication modifications, and therapeutic recommendations. This method makes it easier for patients to get continuing assistance and illness treatment while also lessening the strain of travel, particularly for those with limited mobility. By offering instructional materials, self-management tools, and online support groups, digital health platforms also provide patients and carers more authority and encourage patient participation and treatment plan adherence.
We have various report editions of Neurodegenerative Disease Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape: Neurodegenerative Diseases Market
Major market participants who are essential in determining consumer preferences and market dynamics have a major impact on the neurodegenerative diseases market. These major players provide consumers with easy access to a vast array of wardrobe options through their extensive retail networks and online platforms. Product adoption has increased as a result of their strong worldwide presence and well-known brand, which has also increased consumer trust and loyalty. In addition, these industry titans never stop funding R&D, bringing cutting-edge styles, materials, and practical features to clothing wardrobes to meet changing customer demands and preferences. These big players' combined efforts have a big impact on the market's future direction and level of competition
Top Companies Market Share in Neurodegenerative Disease Industry: (In no particular order of Rank)
- Novartis
- Pfizer
- Merck Serono
- Biogen Idec
- TEVA
- UCB
- Boehringer Ingelheim
- Sanofi
- GlaxoSmithKline
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Which Region will dominate the Market in 2024?
North America dominates the market for neurodegenerative diseases market. Pharmaceutical corporations, academic organisations, and healthcare providers actively working to advance the area are part of a strong ecosystem in North America. Patients in the area suffering from neurodegenerative illnesses have hope for better outcomes and a higher quality of life because of clinical trials, partnerships, and regulatory actions that are continuously changing the landscape. The availability of government assistance, private finance, and venture capital promotes innovation and hastens the creation of cutting-edge treatments for neurodegenerative illnesses.
Which Region is Expanding at the Fastest CAGR?
Europe is the second-largest market, with a revenue of USD xx million in 2024. It is expected to reach a value of USD xx million by 2031, with a CAGR of xx% over the forecast period. Global businesses focused on creating neurodegenerative medication development have a large presence in Germany. Furthermore, the market under study is anticipated to be driven by rising disease awareness and a rise in medication launches by significant pharmaceutical firms in the nation as a result of the rising incidence of various ailments. The UK has a leading position in the neurodegenerative illness market thanks to its advanced medical facilities, robust scientific research base, and government funding for the life sciences. A comprehensive strategy is given priority in government policies on long-term care for individuals suffering from neurodegenerative disorders. This includes providing access to specialised healthcare services, community-based support programmes, and carer respite services.
The current report Scope analyzes Neurodegenerative Disease Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Neurodegenerative Disease Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Neurodegenerative Disease Market Analysis
Global Neurodegenerative Disease Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Neurodegenerative Disease Industry growth. Neurodegenerative Disease market has been segmented with the help of its Disease indication, Drug Distribution Channel, and others. Neurodegenerative Disease market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Neurodegenerative Disease Market Disease Indication Segment Analysis
- Parkinson's' Disease
- Alzheimer's Disease
- Multiple Sclerosis
- Huntington's Disease
Based on disease indication, the Alzheimer's disease segment is accounted to hold a market share of xx% in 2024, reflecting the profound impact of the neurodegenerative disorder on global healthcare systems and society at large. The ageing population and increased life expectancy are contributing to an increase in the prevalence of Alzheimer's disease and increasing the need for efficient therapies and treatments. There is a large unmet demand in the market due to the few treatment choices available for Alzheimer's disease, despite extensive research efforts. Research groups and pharmaceutical corporations are working harder to create disease-modifying treatments that go after underlying pathological processes like tau and amyloid-beta protein aggregation. To effectively address the complex problems posed by Alzheimer's disease and improve patient outcomes in the years to come, it will be imperative to implement initiatives aiming at early detection and diagnosis as well as methods to offer comprehensive care and support for patients and carers.
• For instance, The National Institute of Environmental Health Sciences data updated in June 2022 stated an estimated 6.2 million people might have Alzheimer's disease in the United States, and nearly a million Americans are living with Parkinson's disease.
(Source:https://www.niehs.nih.gov/research/supported/health/neurodegenerative )
Neurodegenerative Disease Market Share (%) by Disease indication in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Neurodegenerative Disease Industry. Request a Free Sample PDF!
Neurodegenerative Disease Market Drug Segment Analysis
- N-Methyl-D-Aspartate Receptor Antagonists
- Cholinesterase Inhibitors
- Dopamine Agonists
- Immunomodulatory Drugs
Based on the drug class, the immunomodulators segment is accounted to hold a market share of xx% in 2024. The segment underscores the growing significance of the drug class in the treatment of neurodegenerative diseases. Immunomodulators are crucial for controlling the immune response in diseases such as Parkinson's, Alzheimer's, and multiple sclerosis. The discovery and use of immunomodulatory medicines have been accelerated by our growing awareness of the roles that inflammation and immunological dysregulation play in neurodegenerative diseases. By focusing on underlying inflammatory pathways, the medications have the potential to alter the course of the disease, giving patients hope for better outcomes and symptom control. The segment's expansion will be further fueled in the next years by ongoing research and development activities aimed at discovering novel immunomodulatory targets and improving treatment plans.
Neurodegenerative Disease Market Share (%) by Drug in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Neurodegenerative Disease Distribution Channel Segment Analysis
The neurodegenerative drugs market is classified into hospital pharmacies, online providers, and drug store & retail pharmacies. The drug store & retail pharmacies held the largest market share in 2024 and are expected to remain dominant throughout the forecast period. This is explained by the rise in patients with neurological conditions like Parkinson's and Alzheimer's, which raises the demand for medications at pharmacies and pharmacy stores. Nonetheless, during the forecast period, the internet providers’ category is anticipated to record the greatest CAGR. This is credited to technical developments, accessibility, affordability, and ease of use.
- Hospital Pharmacies
- Online Providers
- Drug Store & Retail Pharmacy
Author's Detail
David FullerSenior Analyst at Cognitive Market Research
I am working as a Senior Analyst with Cognitive Market Research in the areas of Industry Survey and Market Research/Analytics. I collaborate with CXOs, VPs, and other senior executives to understand their data needs and provide solutions and business strategy building.
I am working as a Senior Analyst with Cognitive Market Research in the areas of Industry Survey and Market Research/Analytics. I collaborate with CXOs, VPs, and other senior executives to understand their data needs and provide solutions and business strategy building. I fulfill data requirements with thorough research and analytics. ME and My research team provide intelligence on industry stats, market structure, company profiles/Competition Analysis, Forecast Mapping, and Recently started providing the COVID-19 Impact Analysis.
Specialties: Industry research, Company analysis, Location Strategy, Tech Research, Change Management, Process Improvement, Peer Group Benchmarking, Startup Ecosystem, Crypto Research, COVID19 Impact Analysis, etc.
Author's Conclusion
The gradual degradation of the structure and function of the central or peripheral nervous systems is a hallmark of a wide spectrum of illnesses known as neurodegenerative diseases. There is a large unmet demand in the market due to the few treatment choices available for Alzheimer's disease, despite extensive research efforts. Research groups and pharmaceutical corporations are working harder to create disease-modifying treatments that go after underlying pathological processes like tau and amyloid-beta protein aggregation. Major market participants who are essential in determining consumer preferences and market dynamics have a major impact on the neurodegenerative diseases market.
Frequently Asked Questions
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Neurodegenerative Disease Market
Sources from Manufacturing & Construction Industry
-
https://www.epa.gov/regulatory-information-sector/construction-sector-naics-23
-
https://www.usace.army.mil/Missions/Civil-Works/Engineering-and-Construction/
-
https://www.abs.gov.au/statistics/industry/building-and-construction
-
https://business.gov.au/planning/industry-information/construction-industry
-
https://www.usitc.gov/research_and_analysis/tradeshifts/2021/footwear
Neurodegenerative Disease Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Disease indication | Parkinson's' Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington's Disease |
| Drug | N-Methyl-D-Aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs |
| Distribution Channel | Hospital Pharmacies, Online Providers, Drug Store & Retail Pharmacy |
| List of Competitors | Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi, GlaxoSmithKline |
This chapter will help you gain GLOBAL Market Analysis of Neurodegenerative Disease. Further deep in this chapter, you will be able to review Global Neurodegenerative Disease Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Neurodegenerative Disease Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Neurodegenerative Disease Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Neurodegenerative Disease Revenue Market Size By Region
-
-
1.3 Global Neurodegenerative Disease Market Size By Disease indication 2019 -2031
-
1.3.1 Parkinson's' Disease Market Size
-
1.3.2 Alzheimer's Disease Market Size
-
1.3.3 Multiple Sclerosis Market Size
-
1.3.4 Huntington's Disease Market Size
-
-
1.4 Global Neurodegenerative Disease Market Size By Drug 2019 -2031
-
1.4.1 N-Methyl-D-Aspartate Receptor Antagonists Market Size
-
1.4.2 Cholinesterase Inhibitors Market Size
-
1.4.3 Dopamine Agonists Market Size
-
1.4.4 Immunomodulatory Drugs Market Size
-
-
1.5 Global Neurodegenerative Disease Market Size By Distribution Channel 2019 -2031
-
1.5.1 Hospital Pharmacies Market Size
-
1.5.2 Online Providers Market Size
-
1.5.3 Drug Store & Retail Pharmacy Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.7.2 Global Market Revenue Split By Disease indication
-
1.7.3 Global Market Revenue Split By Drug
-
1.7.4 Global Market Revenue Split By Distribution Channel
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
Chapter 2 North America Market Analysis
-
2.1 North America Neurodegenerative Disease Market Size 2019 - 2031
-
2.1.1 North America Neurodegenerative Disease Market Size By Country 2019 - 2031
-
2.1.2 North America Neurodegenerative Disease Market Size by Disease indication 2019 -2031
-
2.1.2.1 North America Parkinson's' Disease Market Size
-
2.1.2.2 North America Alzheimer's Disease Market Size
-
2.1.2.3 North America Multiple Sclerosis Market Size
-
2.1.2.4 North America Huntington's Disease Market Size
-
-
2.1.3 North America Neurodegenerative Disease Market Size by Drug 2019 -2031
-
2.1.3.1 North America N-Methyl-D-Aspartate Receptor Antagonists Market Size
-
2.1.3.2 North America Cholinesterase Inhibitors Market Size
-
2.1.3.3 North America Dopamine Agonists Market Size
-
2.1.3.4 North America Immunomodulatory Drugs Market Size
-
-
2.1.4 North America Neurodegenerative Disease Market Size by Distribution Channel 2019 -2031
-
2.1.4.1 North America Hospital Pharmacies Market Size
-
2.1.4.2 North America Online Providers Market Size
-
2.1.4.3 North America Drug Store & Retail Pharmacy Market Size
-
-
Chapter 3 Europe Market Analysis
-
3.1 Europe Neurodegenerative Disease Market Size 2019 - 2031
-
3.1.1 Europe Neurodegenerative Disease Market Size By Country 2019 - 2031
-
3.1.2 Europe Neurodegenerative Disease Market Size by Disease indication 2019 -2031
-
3.1.2.1 Europe Parkinson's' Disease Market Size
-
3.1.2.2 Europe Alzheimer's Disease Market Size
-
3.1.2.3 Europe Multiple Sclerosis Market Size
-
3.1.2.4 Europe Huntington's Disease Market Size
-
-
3.1.3 Europe Neurodegenerative Disease Market Size by Drug 2019 -2031
-
3.1.3.1 Europe N-Methyl-D-Aspartate Receptor Antagonists Market Size
-
3.1.3.2 Europe Cholinesterase Inhibitors Market Size
-
3.1.3.3 Europe Dopamine Agonists Market Size
-
3.1.3.4 Europe Immunomodulatory Drugs Market Size
-
-
3.1.4 Europe Neurodegenerative Disease Market Size by Distribution Channel 2019 -2031
-
3.1.4.1 Europe Hospital Pharmacies Market Size
-
3.1.4.2 Europe Online Providers Market Size
-
3.1.4.3 Europe Drug Store & Retail Pharmacy Market Size
-
-
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Neurodegenerative Disease Market Size 2019 - 2031
-
4.1.1 Asia Pacific Neurodegenerative Disease Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Neurodegenerative Disease Market Size by Disease indication 2019 -2031
-
4.1.2.1 Asia Pacific Parkinson's' Disease Market Size
-
4.1.2.2 Asia Pacific Alzheimer's Disease Market Size
-
4.1.2.3 Asia Pacific Multiple Sclerosis Market Size
-
4.1.2.4 Asia Pacific Huntington's Disease Market Size
-
-
4.1.3 Asia Pacific Neurodegenerative Disease Market Size by Drug 2019 -2031
-
4.1.3.1 Asia Pacific N-Methyl-D-Aspartate Receptor Antagonists Market Size
-
4.1.3.2 Asia Pacific Cholinesterase Inhibitors Market Size
-
4.1.3.3 Asia Pacific Dopamine Agonists Market Size
-
4.1.3.4 Asia Pacific Immunomodulatory Drugs Market Size
-
-
4.1.4 Asia Pacific Neurodegenerative Disease Market Size by Distribution Channel 2019 -2031
-
4.1.4.1 Asia Pacific Hospital Pharmacies Market Size
-
4.1.4.2 Asia Pacific Online Providers Market Size
-
4.1.4.3 Asia Pacific Drug Store & Retail Pharmacy Market Size
-
-
Chapter 5 South America Market Analysis
-
5.1 South America Neurodegenerative Disease Market Size 2019 - 2031
-
5.1.1 South America Neurodegenerative Disease Market Size By Country 2019 - 2031
-
5.1.2 South America Neurodegenerative Disease Market Size by Disease indication 2019 -2031
-
5.1.2.1 South America Parkinson's' Disease Market Size
-
5.1.2.2 South America Alzheimer's Disease Market Size
-
5.1.2.3 South America Multiple Sclerosis Market Size
-
5.1.2.4 South America Huntington's Disease Market Size
-
-
5.1.3 South America Neurodegenerative Disease Market Size by Drug 2019 -2031
-
5.1.3.1 South America N-Methyl-D-Aspartate Receptor Antagonists Market Size
-
5.1.3.2 South America Cholinesterase Inhibitors Market Size
-
5.1.3.3 South America Dopamine Agonists Market Size
-
5.1.3.4 South America Immunomodulatory Drugs Market Size
-
-
5.1.4 South America Neurodegenerative Disease Market Size by Distribution Channel 2019 -2031
-
5.1.4.1 South America Hospital Pharmacies Market Size
-
5.1.4.2 South America Online Providers Market Size
-
5.1.4.3 South America Drug Store & Retail Pharmacy Market Size
-
-
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Neurodegenerative Disease Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Neurodegenerative Disease Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Neurodegenerative Disease Market Size by Disease indication 2019 -2031
-
6.1.2.1 Middle East and Africa Parkinson's' Disease Market Size
-
6.1.2.2 Middle East and Africa Alzheimer's Disease Market Size
-
6.1.2.3 Middle East and Africa Multiple Sclerosis Market Size
-
6.1.2.4 Middle East and Africa Huntington's Disease Market Size
-
-
6.1.3 Middle East and Africa Neurodegenerative Disease Market Size by Drug 2019 -2031
-
6.1.3.1 Middle East and Africa N-Methyl-D-Aspartate Receptor Antagonists Market Size
-
6.1.3.2 Middle East and Africa Cholinesterase Inhibitors Market Size
-
6.1.3.3 Middle East and Africa Dopamine Agonists Market Size
-
6.1.3.4 Middle East and Africa Immunomodulatory Drugs Market Size
-
-
6.1.4 Middle East and Africa Neurodegenerative Disease Market Size by Distribution Channel 2019 -2031
-
6.1.4.1 Middle East and Africa Hospital Pharmacies Market Size
-
6.1.4.2 Middle East and Africa Online Providers Market Size
-
6.1.4.3 Middle East and Africa Drug Store & Retail Pharmacy Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Neurodegenerative Disease Market Size by Disease indication 2019 -2031
-
7.1.2 Country 1Neurodegenerative Disease Market Size by Drug 2019 -2031
-
7.1.3 Country 1Neurodegenerative Disease Market Size by Distribution Channel 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Neurodegenerative Disease Market Revenue and Share by Manufacturers (2019-2023)
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Novartis
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Pfizer
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 Merck Serono
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Biogen Idec
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 TEVA
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 UCB
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 Boehringer Ingelheim
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 Sanofi
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 GlaxoSmithKline
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Trends
-
9.3 Market Restraints
-
9.4 Market Opportunity
-
9.5 Product Life Cycle (Subject to Data Availability)
-
9.6 Industrial Chain Analysis (Subject to Data Availability)
-
9.6.1 Industry Chain Analysis
-
9.6.2 Manufacturing Cost Analysis
-
9.6.3 Consumer Preference Analysis
-
9.6.4 Supply Side Analysis
-
9.6.4.1 Raw Material Analysis
-
9.6.4.2 Raw Material Procurement Analysis
-
9.6.4.3 Raw Material Price Trend Analysis
-
-
-
9.7 Market Attractiveness Analysis
-
9.8 PESTEL Analysis
-
9.9 Porter’s Five Forces Analysis
-
9.10 Patent Analysis (Subject to Data Availability)
-
9.11 ESG Analysis
-
9.12 Technological Road Map
Segmentation Disease indication Analysis 2019 -2031, will provide market size split by Disease indication. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Disease indication Analysis 2019 -2031
-
10.1 Parkinson's' Disease
-
10.1.1 Global Neurodegenerative Disease Revenue Market Size and Share by Parkinson's' Disease 2019 -2031
-
-
10.2 Alzheimer's Disease
-
10.2.1 Global Neurodegenerative Disease Revenue Market Size and Share by Alzheimer's Disease 2019 -2031
-
-
10.3 Multiple Sclerosis
-
10.3.1 Global Neurodegenerative Disease Revenue Market Size and Share by Multiple Sclerosis 2019 -2031
-
-
10.4 Huntington's Disease
-
10.4.1 Global Neurodegenerative Disease Revenue Market Size and Share by Huntington's Disease 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Drug Analysis 2019 -2031
-
11.1 N-Methyl-D-Aspartate Receptor Antagonists
-
11.1.1 Global Neurodegenerative Disease Revenue Market Size and Share by N-Methyl-D-Aspartate Receptor Antagonists 2019 - 2031
-
-
11.2 Cholinesterase Inhibitors
-
11.2.1 Global Neurodegenerative Disease Revenue Market Size and Share by Cholinesterase Inhibitors 2019 - 2031
-
-
11.3 Dopamine Agonists
-
11.3.1 Global Neurodegenerative Disease Revenue Market Size and Share by Dopamine Agonists 2019 - 2031
-
-
11.4 Immunomodulatory Drugs
-
11.4.1 Global Neurodegenerative Disease Revenue Market Size and Share by Immunomodulatory Drugs 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Distribution Channel Analysis 2019 -2031
-
12.1 Hospital Pharmacies
-
12.1.1 Global Neurodegenerative Disease Revenue Market Size and Share by Hospital Pharmacies 2019 -2031
-
-
12.2 Online Providers
-
12.2.1 Global Neurodegenerative Disease Revenue Market Size and Share by Online Providers 2019 -2031
-
-
12.3 Drug Store & Retail Pharmacy
-
12.3.1 Global Neurodegenerative Disease Revenue Market Size and Share by Drug Store & Retail Pharmacy 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Neurodegenerative Disease market
Chapter 13 Research Findings
-
13.1 Key Takeaways
-
13.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
13.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by David Fuller and Team
- 1.1 Neurodegenerative Disease Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Neurodegenerative Disease Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Neurodegenerative Disease Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Neurodegenerative Disease Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Neurodegenerative Disease Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Neurodegenerative Disease Market
Key Questions Answered By Neurodegenerative Disease Market Report 2024
| Why Parkinson's' Disease have a significant impact on Neurodegenerative Disease market? |
| What are the key factors affecting the Parkinson's' Disease and Alzheimer's Disease of Neurodegenerative Disease Market? |
| What is the CAGR/Growth Rate of N-Methyl-D-Aspartate Receptor Antagonists during the forecast period? |
| By type, which segment accounted for largest share of the global Neurodegenerative Disease Market? |
| Which region is expected to dominate the global Neurodegenerative Disease Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
